Naives, nonresponders, relapsers: who is there left to treat?

Archita P Desai, Nancy Reau

Journal: Clinics in liver disease 2011;15(3):483-95

PMID: 21867932

Full Text on Elsevier Science View on PubMed

Abstract

Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.

Address: Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA.

DOI: 10.1016/j.cld.2011.05.011

Link outs

Free resources

Medical:

https://medlineplus.gov/hepatitisc.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Antiviral Agents, Cost of Illness, Hepatitis C, Hepatitis C, Chronic, Humans, Incidence, Prevalence, Recurrence